• Tonix published a research presentation outlining TNX-4800, a long-acting bactericidal human monoclonal antibody being developed to prevent Lyme disease.
• Program targets OspA on Borrelia burgdorferi, cited as the cause of 99.9% of U.S. Lyme disease cases.
• Phase 1 study (NCT04863287) completed, reporting no significant clinical or laboratory safety signals in healthy adults.
• Development plan calls for 2 subcutaneous doses, 450 mg each, with a booster at about 12 weeks; protection expected within 2 days for at least 6 months.
• Company is planning an adaptive Phase 2 field study, pending FDA agreement; GMP manufacturing work is underway for 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.